

This article was originally published [here](#)

ADC Therapeutics is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Freenome's platform will characterize

The post [ADC Therapeutics and Freenome enter biomarker development collaboration](#) appeared first on [Pharmaceutical Business review](#).